NVS Novartis AG

   By Cecilia Butini 
 

Novartis AG said Monday that its Phase 4 trial of migraine drug Aimovig met its primary and secondary endpoints, determining the tolerability and efficacy of the drug against an anticonvulsant treatment.

The Swiss pharmaceutical company said the study, named HER-MES, enrolled 777 adult patients suffering from migraine who were naive to, not suitable for or had previously failed up to three treatments.

Novartis said that as the primary endpoint of the study, Aimovig showed superior tolerability against anticonvulsant drug topiramate, which meant that more patients remained on Aimovig treatment compared with the other drug.

As the secondary endpoint, the study proved the superiority of Aimovig in reducing monthly migraine days in patients, the company said. The safety profile of the drug was consistent with what was seen in previous trials, Novartis said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

November 02, 2020 02:03 ET (07:03 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.